These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6165826)

  • 1. Effect of xylometazoline nasal spray on nasal conductance in subjects with coryza.
    Hamilton LH
    J Otolaryngol; 1981 Apr; 10(2):109-16. PubMed ID: 6165826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nasal decongestant effect of xylometazoline in the common cold.
    Eccles R; Eriksson M; Garreffa S; Chen SC
    Am J Rhinol; 2008; 22(5):491-6. PubMed ID: 18655753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold.
    Eccles R; Martensson K; Chen SC
    Curr Med Res Opin; 2010 Apr; 26(4):889-99. PubMed ID: 20151787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Decongestant nasal spray. Results of a rhinomanometric double-blind study].
    Maranta CA; Simmen D
    Schweiz Med Wochenschr; 1996 Nov; 126(44):1875-80. PubMed ID: 8984600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhinomanometry and MRI.
    Caenen M; Hamels K; Deron P; Clement P
    Rhinology; 2005 Sep; 43(3):205-9. PubMed ID: 16218514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold.
    Eccles R; Jawad MS; Jawad SS; Angello JT; Druce HM
    Am J Rhinol; 2005; 19(1):25-31. PubMed ID: 15794071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
    Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
    Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decongestant activity of a new formulation of xylometazoline nasal spray: a double-blind, randomized versus placebo and reference drugs controlled, dose-effect study.
    Castellano F; Mautone G
    Drugs Exp Clin Res; 2002; 28(1):27-35. PubMed ID: 12073765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold.
    Hagen M; Clark K; Kalita P; Serra G; Sanchez E; Varbiro G; Albasser MM
    Ther Adv Respir Dis; 2024; 18():17534666241228927. PubMed ID: 38372128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OTC use of a topical nasal spray solution containing xylometazoline plus ipratropium in patients with common cold.
    Strandell B; Norgren-Holst E; Tran N; Jakobsen HB; Chen S
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):744-51. PubMed ID: 19954713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal airway resistance after decongestion with a nasal spray or a bellows device.
    Jessen M; Ivarsson A; Malm L
    Rhinology; 1996 Mar; 34(1):28-31. PubMed ID: 8739865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant.
    Ferguson EA; Eccles R
    Acta Otolaryngol; 1997 Jul; 117(4):614-7. PubMed ID: 9288222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of topical tuaminoheptane combined with N-acetyl-cysteine in reducing nasal resistance. A double-blind rhinomanometric study versus xylometazoline and placebo.
    Cogo A; Chieffo A; Farinatti M; Ciaccia A
    Arzneimittelforschung; 1996 Apr; 46(4):385-8. PubMed ID: 8740084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does nasal decongestion improve obstructive sleep apnea?
    Clarenbach CF; Kohler M; Senn O; Thurnheer R; Bloch KE
    J Sleep Res; 2008 Dec; 17(4):444-9. PubMed ID: 18710420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: a double-blind, placebo-controlled clinical trial.
    Eby GA; Halcomb WW
    Altern Ther Health Med; 2006; 12(1):34-8. PubMed ID: 16454145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with xylometazoline (Otrivin) nosedrops over a six-week period.
    Petruson B
    Rhinology; 1981 Sep; 19(3):167-72. PubMed ID: 6171024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of topical combinations of ipratropium and xylometazoline for the treatment of symptoms of runny nose and nasal congestion associated with acute upper respiratory tract infection.
    Eccles R; Pedersen A; Regberg D; Tulento H; Borum P; Stjärne P
    Am J Rhinol; 2007; 21(1):40-5. PubMed ID: 17283559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal airflow asymmetry and the effects of a topical nasal decongestant.
    Williams RG; Eccles R
    Rhinology; 1992 Dec; 30(4):277-82. PubMed ID: 1281924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling.
    Graf P; Juto JE
    Rhinology; 1995 Mar; 33(1):14-7. PubMed ID: 7540314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate effect of benzalkonium chloride in decongestant nasal spray on the human nasal mucosal temperature.
    Lindemann J; Leiacker R; Wiesmiller K; Rettinger G; Keck T
    Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):357-61. PubMed ID: 15270822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.